PT3416964T - Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro - Google Patents
Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancroInfo
- Publication number
- PT3416964T PT3416964T PT177527421T PT17752742T PT3416964T PT 3416964 T PT3416964 T PT 3416964T PT 177527421 T PT177527421 T PT 177527421T PT 17752742 T PT17752742 T PT 17752742T PT 3416964 T PT3416964 T PT 3416964T
- Authority
- PT
- Portugal
- Prior art keywords
- derivatives useful
- carboxamide derivatives
- rsk inhibitors
- rsk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297522P | 2016-02-19 | 2016-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3416964T true PT3416964T (pt) | 2021-03-09 |
Family
ID=59625645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177527421T PT3416964T (pt) | 2016-02-19 | 2017-02-17 | Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9771366B2 (pt) |
| EP (2) | EP3848373A1 (pt) |
| JP (2) | JP6912486B2 (pt) |
| KR (1) | KR20180129783A (pt) |
| CN (2) | CN113620950A (pt) |
| AU (1) | AU2017220738B2 (pt) |
| BR (1) | BR112018016968A2 (pt) |
| CA (1) | CA3014395A1 (pt) |
| CO (1) | CO2018008846A2 (pt) |
| DK (1) | DK3416964T3 (pt) |
| ES (1) | ES2858753T3 (pt) |
| IL (1) | IL261170B (pt) |
| MX (1) | MX2018010028A (pt) |
| PL (1) | PL3416964T3 (pt) |
| PT (1) | PT3416964T (pt) |
| WO (1) | WO2017141116A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2016150884A1 (en) | 2015-03-20 | 2016-09-29 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
| DK3303339T3 (da) | 2015-07-07 | 2021-04-12 | H Lundbeck As | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme |
| EP3402489B1 (en) | 2016-01-15 | 2021-06-09 | Orbsen Therapeutics Limited | Sdc-2 exosome compositions and methods of isolation and use |
| AU2017220738B2 (en) | 2016-02-19 | 2022-02-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as RSK inhibitors |
| AU2018300272A1 (en) | 2017-07-14 | 2020-02-06 | Orbsen Therapeutics Limited | CD39 stromal stem cells methods of isolation and use |
| CN109847063B (zh) * | 2018-12-26 | 2023-02-28 | 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） | Rsk信号通路抑制剂在抑制沙眼衣原体感染中的应用 |
| CN109438403A (zh) * | 2018-12-28 | 2019-03-08 | 凯瑞斯德生化(苏州)有限公司 | 一种5-氨基苯并呋喃-2-甲酸乙酯的制备方法 |
| CN113677681A (zh) * | 2019-02-11 | 2021-11-19 | 凤凰分子设计公司 | Rsk抑制剂的结晶形式 |
| TW202307005A (zh) * | 2021-05-28 | 2023-02-16 | 美商邊際分析公司 | 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法 |
| WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| WO2023236960A1 (zh) * | 2022-06-07 | 2023-12-14 | 上海科恩泰生物医药科技有限公司 | 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5792763A (en) | 1996-10-08 | 1998-08-11 | Eli Lilly And Company | Serotonin 5-HT1F agonists |
| ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| JP2001524124A (ja) | 1997-05-07 | 2001-11-27 | ガレン（ケミカルズ）リミティド | テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具 |
| US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| AU2003224257A1 (en) | 2002-04-09 | 2003-10-27 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| LT2489659T (lt) * | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| FR2884516B1 (fr) | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| CA2690410C (en) * | 2007-06-12 | 2015-09-29 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
| CN101855203B (zh) | 2007-09-14 | 2014-03-19 | 密执安州立大学董事会 | F1f0-atp合成酶抑制剂以及相关的方法 |
| GB0718870D0 (en) | 2007-09-27 | 2007-11-07 | Univ Dundee | Modulation of RSK |
| EP2509980A1 (en) | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Heterocyclic compounds containing an indole core |
| EP2509979B1 (en) | 2009-12-07 | 2016-05-25 | Boehringer Ingelheim International GmbH | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| CA2913583C (en) | 2012-06-04 | 2019-08-06 | Phoenix Molecular Diagnostics Ltd. | Methods of inhibiting rsk for treatment of breast cancer |
| US9278950B2 (en) * | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CN103724251B (zh) * | 2014-01-18 | 2015-07-22 | 福州大学 | 一种靶向stat3的小分子化合物及其制备方法和应用 |
| JP6518690B2 (ja) | 2014-04-07 | 2019-05-22 | ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． | （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン |
| AU2017220738B2 (en) | 2016-02-19 | 2022-02-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as RSK inhibitors |
-
2017
- 2017-02-17 AU AU2017220738A patent/AU2017220738B2/en active Active
- 2017-02-17 MX MX2018010028A patent/MX2018010028A/es active IP Right Grant
- 2017-02-17 ES ES17752742T patent/ES2858753T3/es active Active
- 2017-02-17 PL PL17752742T patent/PL3416964T3/pl unknown
- 2017-02-17 KR KR1020187027085A patent/KR20180129783A/ko not_active Application Discontinuation
- 2017-02-17 EP EP20211105.0A patent/EP3848373A1/en active Pending
- 2017-02-17 US US15/436,587 patent/US9771366B2/en active Active
- 2017-02-17 CN CN202110838177.9A patent/CN113620950A/zh active Pending
- 2017-02-17 EP EP17752742.1A patent/EP3416964B1/en active Active
- 2017-02-17 CA CA3014395A patent/CA3014395A1/en active Pending
- 2017-02-17 WO PCT/IB2017/000237 patent/WO2017141116A1/en active Application Filing
- 2017-02-17 PT PT177527421T patent/PT3416964T/pt unknown
- 2017-02-17 JP JP2018543101A patent/JP6912486B2/ja active Active
- 2017-02-17 DK DK17752742.1T patent/DK3416964T3/da active
- 2017-02-17 CN CN201780024735.XA patent/CN109071542B/zh active Active
- 2017-02-17 US US16/077,029 patent/US10758530B2/en active Active
- 2017-02-17 BR BR112018016968A patent/BR112018016968A2/pt active Search and Examination
- 2017-07-31 US US15/665,181 patent/US10081632B2/en active Active
-
2018
- 2018-08-15 IL IL261170A patent/IL261170B/en unknown
- 2018-08-24 CO CONC2018/0008846A patent/CO2018008846A2/es unknown
-
2020
- 2020-06-30 US US16/917,595 patent/US20210186961A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112227A patent/JP7289876B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019505541A (ja) | 2019-02-28 |
| CN113620950A (zh) | 2021-11-09 |
| MX2018010028A (es) | 2019-01-21 |
| CN109071542A (zh) | 2018-12-21 |
| JP7289876B2 (ja) | 2023-06-12 |
| US9771366B2 (en) | 2017-09-26 |
| US10081632B2 (en) | 2018-09-25 |
| DK3416964T3 (da) | 2021-02-22 |
| EP3848373A1 (en) | 2021-07-14 |
| ES2858753T3 (es) | 2021-09-30 |
| EP3416964A1 (en) | 2018-12-26 |
| AU2017220738A1 (en) | 2018-08-30 |
| US10758530B2 (en) | 2020-09-01 |
| KR20180129783A (ko) | 2018-12-05 |
| IL261170B (en) | 2021-12-01 |
| US20170327501A1 (en) | 2017-11-16 |
| WO2017141116A8 (en) | 2017-12-28 |
| CN109071542B (zh) | 2021-07-20 |
| WO2017141116A1 (en) | 2017-08-24 |
| US20210186961A1 (en) | 2021-06-24 |
| IL261170A (en) | 2018-10-31 |
| JP6912486B2 (ja) | 2021-08-04 |
| EP3416964B1 (en) | 2020-12-16 |
| US20170240549A1 (en) | 2017-08-24 |
| CO2018008846A2 (es) | 2018-11-13 |
| PL3416964T3 (pl) | 2021-10-18 |
| BR112018016968A2 (pt) | 2019-01-08 |
| CA3014395A1 (en) | 2017-08-24 |
| US20190134029A1 (en) | 2019-05-09 |
| EP3416964A4 (en) | 2019-09-18 |
| AU2017220738B2 (en) | 2022-02-24 |
| JP2021176857A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| IL261170A (en) | History of carboxamide used as rsk inhibitors | |
| HK1255269A1 (zh) | 作為parp抑制劑的雜芳基衍生物 | |
| IL256393A (en) | History of affluent polycyclic as cdk9 inhibitors | |
| ZA201607658B (en) | Carboxamide derivatives | |
| AP2016009554A0 (en) | Carboxamide derivatives | |
| HK1257565A1 (zh) | 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物 | |
| HK1257567A1 (zh) | 作為htra1抑制劑的新型二氟酮酰胺衍生物 | |
| HK1253572A1 (zh) | 作為tnap抑制劑的吡啶並噁嗪酮化合物 | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| EP3526216C0 (en) | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | |
| IL248801A0 (en) | Carboxamide history |